Andreas Rummelt Email & Phone Number

Andreas Rummelt Work

• Chairman @ InterPharmaLink AG (April 2017 - Present)
• Member of the Board of Directors @ Cypralis Limited (July 2013), Alvogen (April 2016), Leukocare AG (July 2016) (January 2013 - Present)
• Member of the Board of Directors @ AstraZeneca (August 2021 - April 2025)
• Member of the Board of Directors @ Xellia Pharmaceuticals A/S (January 2012 - May 2024)
• Member of the Board of Directors @ PolgenX A (Holding company of Polyplus-transfection) (September 2020 - July 2023)
• Member of the Scientific Advisory Committee @ Global Antibiotic R&D Partnership (GARDP) (January 2020 - May 2023)
• Managing Partner @ InterPharmaLink AG, Basel (January 2011 - February 2023)
• Member of the Board of Directors @ Alexion Pharmaceuticals, Inc. (January 2010 - July 2021)
• Member of the Board of Directors @ Habasit (October 2013 - April 2018)
• Member of the Board of Directors @ Acino Holding AG (April 2011 - December 2013)
• Group Head Quality Assurance and Technical Operations, Member of the Novartis Executive Committee @ Novartis AG (December 2008 - January 2010)
• CEO Sandoz, Member of the Novartis Executive Committee @ Novartis AG (October 2004 - November 2008)
• Global Head Technical Operations, Member of the Pharma Executive Committee @ Novartis Pharma AG (September 1999 - September 2004)
• Global Head Technical Research and Development, Novartis Pharma Development, Basel and Switzerland @ Novartis Pharma AG (January 1997 - August 1999)
• Global Head Technical Research and Development, Sandoz Pharma Development, Basel and Switzerland @ Sandoz AG (January 1994 - December 1996)
• Laboratory Head, Group Head, Department Head Drug Delivery Systems, Sandoz Pharma Development Basel and @ Sandoz AG (January 1985 - December 1993)